Jolanda Howe Sells 375 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 375 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $34.00, for a total transaction of $12,750.00. Following the sale, the senior vice president now owns 2,426 shares of the company’s stock, valued at $82,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $33.88 on Friday. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $35.56. The company has a market cap of $1.60 billion, a P/E ratio of -9.13 and a beta of 1.15. The firm has a 50-day moving average of $27.39 and a 200 day moving average of $27.31. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.68 and a quick ratio of 3.47.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. The company had revenue of $69.22 million during the quarter, compared to the consensus estimate of $69.71 million. On average, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC increased its position in shares of Mirum Pharmaceuticals by 34.2% during the first quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after acquiring an additional 704,659 shares in the last quarter. Silvercrest Asset Management Group LLC increased its position in shares of Mirum Pharmaceuticals by 64.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock valued at $4,090,000 after acquiring an additional 63,871 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Mirum Pharmaceuticals by 37.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock valued at $40,131,000 after acquiring an additional 432,824 shares in the last quarter. Affinity Asset Advisors LLC boosted its holdings in Mirum Pharmaceuticals by 220.0% in the first quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock worth $4,019,000 after purchasing an additional 110,000 shares during the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in Mirum Pharmaceuticals by 0.9% in the first quarter. William Blair Investment Management LLC now owns 627,272 shares of the company’s stock worth $15,757,000 after purchasing an additional 5,494 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have issued reports on MIRM. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. JMP Securities increased their target price on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 18th. JPMorgan Chase & Co. increased their target price on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Baird R W upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a report on Monday, June 17th. Finally, Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday, June 17th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $53.64.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.